Immediate Impact
5 from Science/Nature 63 standout
Citing Papers
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
Lung cancer immunotherapy: progress, pitfalls, and promises
2023 Standout
Works of K. Park being referenced
P1.04-001 Osimertinib with Ramucirumab or Necitumumab in Advanced T790M-positive EGFR-Mutant NSCLC: Preliminary Ph1 Study Results
2017
Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC
2016
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| K. Park | 546 | 441 | 71 | 144 | 54 | 763 | |
| Matteo Brighenti | 610 | 305 | 63 | 177 | 38 | 839 | |
| Eric Raefsky | 391 | 240 | 102 | 158 | 45 | 819 | |
| K.A. Newton | 279 | 261 | 40 | 127 | 43 | 766 | |
| Myung Hee Chang | 376 | 242 | 80 | 117 | 49 | 698 | |
| Rémi Veillon | 528 | 418 | 86 | 148 | 68 | 705 | |
| Georg Pall | 354 | 189 | 48 | 158 | 49 | 789 | |
| C Mulatero | 627 | 347 | 72 | 229 | 35 | 878 | |
| Hiroki Ueda | 635 | 304 | 109 | 110 | 56 | 889 | |
| Shuncong Wang | 337 | 203 | 96 | 203 | 38 | 738 | |
| N. J. Vogelzang | 299 | 285 | 88 | 283 | 37 | 750 |
All Works
Loading papers...